Table 3.
Compounds belonging to classes identified by CMap as most opposing to gene expression changes resulting from angiosarcoma.
| Compounds Groups | Enrichment Scores |
|---|---|
| topoisomerase inhibitor | −97.84 |
| ellipticine | −98.37 |
| amsacrine | −98.28 |
| mitoxantrone | −97.89 |
| amonafide | −97.85 |
| topotecan | −97.72 |
| teniposide | −96.72 |
| SN-38 | −96.44 |
| irinotecan | −96.11 |
| camptothecin | −95.88 |
| doxorubicin | −95.42 |
| pidorubicine | −95.28 |
| daunorubicin | −95.14 |
| pirarubicin | −94.78 |
| HDAC inhibitor | −95.95 |
| panobinostat | −98.45 |
| scriptaid | −98.31 |
| THM-I-94 | −97.57 |
| vorinostat | −96.79 |
| belinostat | −96.72 |
| apicidin | −95.00 |
| trichostatin-a | −94.85 |
| ISOX | −94.79 |
| HC-toxin | −94.26 |
| dacinostat | −92.65 |
| givinostat | −91.73 |
| CDK inhibitor | −94.38 |
| PHA-793887 | −97.96 |
| JNJ-7706621 | −97.43 |
| AT-7519 | −95.84 |
| aminopurvalanol-a | −93.70 |
| DNA synthesis inhibitor | −92.69 |
| mitomycin-c | −94.37 |
| JAK inhibitor | −92.60 |
| JAK3-inhibitor-VI | −93.52 |
| TG-101348 | −92.57 |